logo
Share SHARE
FONT-SIZE Plus   Neg

Forest Labs, Pierre Fabre Report Results In Phase III Trial Of Levomilnacipran

Forest Laboratories, Inc. (FRX: Quote) and Pierre Fabre Medicament announced positive top-line results in a Phase III clinical trial of levomilnacipran, an investigational agent for the treatment of adults with major depressive disorder, or MDD.

Treatment with levomilnacipran significantly reduced depression symptoms in patients with MDD versus placebo, as early as week one and at each subsequent visit as measured by the Montgomery-Asberg Depression Rating Scale-Clinician Rated. Levomilnacipran was generally well-tolerated in this study. The premature discontinuation rates were 25 percent for levomilnacipran and 21 percent for placebo. The most common adverse events observed in the levomilnacipran group were nausea, dizziness and constipation.

Results from an additional placebo-controlled Phase III fixed-dose study are expected in Spring 2012.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Hewlett-Packard Co. (HPQ) has filed a lawsuit against Michael Lynch, the co-founder of Autonomy Corp., and its former Financial Chief Sushovan Hussain for a whopping $5.1 billion alleging that the executives misrepresented the financial situation of Autonomy. An HP's spokeswoman confirmed that the... Nine acres of green grass with 400 trees and a half-mile-long walk way. We are not talking about any park, but the expansive rooftop of Facebook's new office. The 430,000 square feet office is a single room and it might be the largest open floor plan in the world. Outrage in the business world may be helping re-shape a new Indiana law that many are calling "anti-gay." Embarrassed and worried about the backlash from the national business community, the state's paper of record is loudly calling on legislators to re-word the law. The front page of the Indianapolis...
comments powered by Disqus
Follow RTT